Terms ending in 2038
Every in-force patent on Oncotherapy Science, Inc.'s record whose computed term ends in 2038, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 11,079,386 | Monoclonal Antibody Against FZD10 and Use Thereof In force · High confidence | Oncotherapy Science, Inc. | In force | High confidence | |
| US 11,066,477 | Monoclonal Antibody Against Melk and Utilization Thereof In force · High confidence | Oncotherapy Science, Inc. | In force | High confidence | |
| US 11,091,517 | Peptide Derivative and Pharmaceutical Composition Containing Same In force · High confidence | Tokushima University | In force | High confidence | |
| US 11,242,365 | FOXM1-DERIVED Peptide, and Vaccine Including Same In force · High confidence | Oncotherapy Science, Inc. | In force | High confidence |
4 of 4 patents shown. Soonest term end first, then patent number.
3 of these are in force and held by Oncotherapy Science, Inc..
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.